Skip to main content
OpenTrials
Completed

NCT Number: NCT02839200

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Investigator Site, Berlin, Germany

Loading trial locations.

About this study

This study consists of the following phases: screening phase; double-blind treatment phase; safety follow-up phase. Safety is monitored throughout the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Principal inclusion Criteria:

  • Signed informed consent prior to any study-mandated procedure.
  • Male or female aged 18-64 years (inclusive).
  • Women of childbearing potential must have negative pregnancy tests and use reliable methods of contraception up to 30 days after EOT.
  • Body mass index (BMI): 18.5 ≤ BMI (kg/m2) < 32.0.
  • Insomnia disorder according to DSM-5 criteria.
  • Insufficient sleep quantity as collected subjectively in the sleep diary and validated objectively by polysomnography.
  • Insomnia Severity Index score ≥ 15.

Principal exclusion Criteria:

  • Any current history of sleep disorder other than insomnia, or any lifetime history of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (REM) behavior disorder, or narcolepsy.
  • Self-reported usual daytime napping ≥ 1 hour per day, and ≥ 3 days per week.
  • Caffeine consumption ≥ 600 mg per day.
  • Shift work within 2 weeks prior to the screening visit, or planned shift work during study.
  • Travel ≥ 3 time zones within 1 week prior to the screening visit, or planned travel > or= 3 time zones during study.
  • Hematology or biochemistry test results deviating from the normal range to a clinically relevant extent as per judgment of the Investigator.
  • AST and/or ALT > 2 × ULN and/or direct bilirubin > 1.5 × ULN (except known history of Gilbert's syndrome).
  • Severe renal impairment (known or defined as estimated creatinine clearance < 30 mL/min).
  • History or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.

Treatment and study plan

ACT-541468 5 mg

Drug

Capsule for oral administration containing ACT-541468 at a strength of 5 mg

ACT-541468 10 mg

Drug

Capsule for oral administration containing ACT-541468 at a strength of 10 mg

ACT-541468 25 mg

Drug

Capsule for oral administration containing ACT-541468 at a strength of 25 mg

zolpidem

Drug

Over-encapsulated zolpidem tablet at a strength of 10 mg

Placebo 1

Drug

Placebo capsules matching ACT-541468 capsules

Placebo 2

Drug

Placebo capsules matching over-encapsulated zolpidem

Primary outcomes

  1. Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2

    Time frame: Baseline and Days 1&2

    WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG)

Secondary outcomes

  1. Change in Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2

    Time frame: Baseline and Days 1&2

    LPS is the duration of time in minutes from lights off to persistent sleep onset as determined by PSG

  2. Change in Subjective Latency to Sleep Onset (sLSO) From Baseline to Week 4

    Time frame: Baseline and Week 4

    sLSO is the self-reported time to fall asleep, as reported in the sleep diary

  3. Change in Subjective Wake After Sleep Onset (sWASO) From Baseline to Week 4

    Time frame: Baseline and Week 4

    sWASO is the self-reported time spent awake after sleep onset as reported in the sleep diary.

Sponsors and collaborators

Lead sponsor

Idorsia Pharmaceuticals Ltd.

Industry

Registry information

Official study title

Multi-center, Double-blind, Randomized, Placebo-controlled, Active-reference, Parallel-group, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Jul 20, 2016
Registry last updated
Apr 13, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.